

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 April 2025 (24.04.2025)



(10) International Publication Number
WO 2025/083237 A1

(51) International Patent Classification:

A61K 31/506 (2006.01) *A61P 11/06* (2006.01)
A61K 9/00 (2006.01) *A61P 17/00* (2006.01)
A61P 3/10 (2006.01) *A61P 37/00* (2006.01)
A61P 11/00 (2006.01)

(21) International Application Number:

PCT/EP2024/079550

(22) International Filing Date:

18 October 2024 (18.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2316063.3 20 October 2023 (20.10.2023) GB

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; 151 85
Södertälje (SE).

(72) Inventors: **BIRRELL, Mark**; 1 Francis Crick Avenue,
Cambridge Biomedical Campus, Cambridge CB2 0AA
(GB). **LOOD, Therese**; 151 85 Södertälje (SE). **FRIDÉN,
Markus**; 151 85 Södertälje (SE). **LUNDAHL, Anna**;
151 85 Södertälje (SE). **HENDRICKX, Ramon**; 151 85
Södertälje (SE).

(74) Agent: **MEWBURN ELLIS LLP**; Aurora Building, Coun-
terslip, Bristol BS1 6BX (GB).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

(54) Title: LONDAMOCITINIB FOR THE TREATMENT OF ASTHMA



(57) Abstract: A compound of Formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment or prophylaxis of a disease or condition in which inhibition of JAK1 is beneficial, wherein said treatment comprises the administration of the Compound of Formula (I) or pharmaceutically acceptable salt thereof, in a daily delivered dose of from 0.8 mg to 6.2 mg of the free base to a subject.

WO 2025/083237 A1